Related Experiment Videos
Metastatic malignant melanoma in pregnancy
K P Harkin1, J E Drumm, P O'Brien
1Coombe Lying-in Hospital, Dolphins Barn, Dublin.
Irish Medical Journal
|September 1, 1990
Summary
Dacarbazine, a chemotherapy drug, was used to treat a pregnant woman with metastatic malignant melanoma, inducing remission and allowing for the birth of a healthy infant. This marks the first documented use of dacarbazine during pregnancy.
Area of Science:
- Oncology
- Maternal-Fetal Medicine
- Pharmacology
Background:
- Malignant melanoma during pregnancy presents significant treatment challenges.
- Systemic chemotherapy options for advanced melanoma in pregnant patients are limited.
- The safety and efficacy of dacarbazine in pregnancy were previously undocumented.
Observation:
- A 29-year-old pregnant patient at 27 weeks gestation presented with disseminated metastatic malignant melanoma.
- The patient received dacarbazine treatment for her advanced cancer.
- Close monitoring of both maternal and fetal well-being was essential.
Findings:
- Dacarbazine treatment resulted in a dramatic remission of the metastatic malignant melanoma.
- The patient spontaneously went into labor at 38 weeks gestation.
- A healthy infant was delivered, with no immediate adverse effects noted in the newborn.
- The patient experienced a relapse of malignant melanoma eight weeks postpartum and subsequently died.
Implications:
- This case report suggests that dacarbazine may induce remission in advanced malignant melanoma during pregnancy.
- The findings highlight the potential for successful pregnancy continuation despite aggressive cancer treatment.
- Further research is warranted to establish the risk-benefit profile of dacarbazine in pregnant oncology patients.
- This case provides crucial data on the first reported use of dacarbazine in pregnancy.